NuCana Cancels Series A Warrants and Ends Jefferies ATM Agreement

Nucana ( (NCNA) ) has shared an announcement.

NuCana plc announced the cancellation of its Series A ADS Purchase Warrants through letter agreements with warrant holders, allowing the company to proceed with an at-the-market (ATM) offering. The warrant holders agreed to waive certain restrictions, enabling NuCana to use proceeds from the ATM offering to make pro rata cash payments for the cancellation of outstanding warrants. Additionally, NuCana terminated its ATM sales agreement with Jefferies LLC, effective June 27, 2025, without incurring termination penalties.

The most recent analyst rating on (NCNA) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.

Spark’s Take on NCNA Stock

According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.

Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.

To see Spark’s full report on NCNA stock, click here.

More about Nucana

NuCana plc is a biotechnology company based in Edinburgh, United Kingdom. The company focuses on developing novel cancer treatments using its proprietary ProTide technology platform.

Average Trading Volume: 143,432,616

Technical Sentiment Signal: Sell

Current Market Cap: $536K

For detailed information about NCNA stock, go to TipRanks’ Stock Analysis page.